LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the "**Company**") on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

Reference is made to the annual report of the Company for the year ended 31 December 2014 (the "**Annual Report**"). As disclosed in the Annual Report, the Company's major products include patent foramen ovale occluder (the "**PFO Occluder**"), LAmbre™ LAA occluder (the "**LAA Occluder**") and iron-based bioresorbable drug-eluting coronary scaffold system (the "**IBS System**"). Both the LAA Occluder and IBS System were approved as innovative medical devices by the China Food and Drug Administration of the People's Republic of China (the "**PRC**") in 2014.

On 12 October 2015, a seminar was held on the latest development of the LAA Occluder at the 27th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics TCT 2015 in San Francisco, the United States of America. It was reported in the aforesaid seminar that as of October 2015, the Company had conducted clinical studies on the LAA Occluder which was successfully implanted in more than 270 patients worldwide since October 2012, including in the PRC, Europe and Southeast Asia. The implantation success rate of the LAA Occluder is approximately 99.6% based on feedback from doctors.

According to the above clinical studies results, the left atrial appendage closure with the LAA Occluder seems to be feasible and safe. The Company believes that the main advantages of the LAA Occluder will include small delivery system, ease of use, the ability to be fully retrievable and repositionable during implantation, and very low risk of device embolization.

On 14 October 2015, A doctor from the Cardiovascular Center Frankfurt (the "**CVC Frankfurt**") reported in relation to the features and clinical studies results of the PFO Occluder. According to the aforesaid report, as of June 2015, the PFO Occluder was implanted in 49 patients in the CVC Frankfurt and the implantation success rate of the PFO Occluder is 100%. The PFO Occluder had completed its premarket clinical evaluations in Germany and France before 2013 and obtained relevant Conformité Européenne (CE) certificates.

On 15 October 2015, the Company's Chief Technology Officer was invited to share the recent development of the IBS System where he updated doctors from around the world that the IBS System currently has mechanical properties comparable to the best existing permanent stent and its total corrosion cycle can be controlled at approximately one year. The IBS System attracts the attention and interests of doctors globally as it is currently the only iron-based biodegradable stent in the world, and has positive animal test results and other advantages.

In light of the satisfactory development of the PFO Occluder, LAA Occluder and IBS System as disclosed above, the Company expects that when launched, the three said products will become significant products to the Company's sales in the future.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 22 October 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. WU Jianhui, Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming being independent non-executive Directors.